Orforglipron Overdose: What Happens If You Take Too Much?
By Ayush Gupta · Published September 21, 2026 · Updated September 21, 2026
Educational information, not medical advice. This guide is for general understanding of oral GLP-1 medicines. Always follow your prescriber's instructions and talk to a qualified clinician about your treatment.
If you’ve taken more orforglipron (Foundayo) than intended, the FDA-approved label doesn’t describe a specific overdose syndrome — its guidance is general: contact Poison Control or a medical toxicologist, and get supportive treatment based on whatever symptoms actually show up. Because the drug clears slowly, a period of observation may be needed rather than a quick resolution. Here’s what the label says, what symptoms to watch for, and when to seek care.
What the FDA label says about overdose
Per the FOUNDAYO label on DailyMed, the overdosage guidance is straightforward and general, not orforglipron-specific:
- Contact Poison Control (1-800-222-1222) or a medical toxicologist for current recommendations.
- Initiate supportive treatment according to the person’s actual clinical signs and symptoms — there isn’t a single standard “overdose protocol” beyond treating what appears.
- A period of observation and treatment may be necessary, considering orforglipron’s half-life. Per the FDA label, that half-life is approximately 29 to 49 hours (see our half-life guide for the full clearance timeline), which is longer than many oral medications — so symptoms aren’t necessarily a same-day issue.
This is a common pattern for GLP-1 receptor agonist labeling generally: there’s no specific antidote, and management centers on supportive care rather than a targeted reversal treatment.
What symptoms could an overdose cause?
The label doesn’t list a distinct set of overdose-specific symptoms, but it’s reasonable to expect an exaggerated version of orforglipron’s known dose-related effects:
| Symptom category | What to watch for |
|---|---|
| Gastrointestinal | Worsened or severe nausea, vomiting, diarrhea, or abdominal discomfort |
| Dehydration (from GI effects) | Dark or infrequent urination, dizziness, unusual thirst, fatigue |
| Low blood sugar (mainly if also on insulin or a sulfonylurea) | Shakiness, sweating, confusion, rapid heartbeat, lightheadedness |
GLP-1 receptor agonists as a class are most strongly associated with gastrointestinal side effects, and those effects tend to be dose-related — meaning more of the drug at once plausibly means more pronounced GI symptoms, even though the label doesn’t quantify this for an overdose scenario specifically. If you’re already managing nausea or vomiting at a normal dose, Managing Orforglipron Nausea and Orforglipron Vomiting cover the day-to-day version of these symptoms; an overdose is the same symptom categories, potentially more intense.
Accidental double dose vs. a true overdose
Not every “I took too much” situation is the same. Two common scenarios:
- Accidentally took two tablets in one day (for example, forgetting you already took it, or trying to “catch up” after a missed dose). The label’s own missed-dose instructions explicitly warn against doubling up for this reason. If this happens, don’t panic, but do call your prescriber or Poison Control to talk through your specific situation rather than assuming it’s automatically fine or automatically dangerous. Our missed dose guide covers the correct way to handle a missed dose so this doesn’t happen in the first place.
- Took a larger quantity than a single extra tablet, whether by mistake or otherwise. This warrants contacting Poison Control (1-800-222-1222) promptly, and emergency care if symptoms are significant.
Either way, the label’s core instruction applies: get guidance based on your actual symptoms rather than guessing at home.
Dehydration and kidney strain risk
Because severe vomiting or diarrhea can lead to dehydration, and dehydration can in turn strain kidney function, an overdose scenario with pronounced GI symptoms is one where that chain is more likely to matter. Our Orforglipron and Kidney Function guide covers the dehydration warning signs worth watching for — dark urine, dizziness, unusual thirst — in more detail. If those appear after taking too much orforglipron, that’s a reason to seek care rather than wait it out.
Does an overdose raise hypoglycemia risk?
Mostly in combination with other glucose-lowering medications. GLP-1 receptor agonists engage a glucose-dependent insulin pathway, which is part of why hypoglycemia isn’t the headline concern with these drugs alone. But if you also take insulin or an insulin secretagogue like a sulfonylurea, taking more orforglipron than intended could plausibly compound that risk. If you’re on any glucose-lowering medication and think you’ve taken too much orforglipron, mention that combination specifically when you call Poison Control or your prescriber.
How this compares across GLP-1 medications
Overdose management for GLP-1 receptor agonists follows a similar general pattern across the class, per MedlinePlus drug information for semaglutide and tirzepatide:
| Orforglipron (Foundayo) | Semaglutide (Ozempic, Wegovy, Rybelsus) | Tirzepatide (Mounjaro, Zepbound) | |
|---|---|---|---|
| Specific antidote | None described | None described, per MedlinePlus | None described, per MedlinePlus |
| General approach | Contact Poison Control; supportive treatment based on symptoms | Contact Poison Control; supportive treatment, per MedlinePlus | Contact Poison Control; supportive treatment, per MedlinePlus |
| Why observation matters | Half-life of ~29–49 hours means effects don’t clear quickly | Longer-acting formulations mean effects can persist, per MedlinePlus | Longer-acting formulations mean effects can persist, per MedlinePlus |
The pattern holds across the class: no targeted reversal treatment, and management built around watching for and treating whatever symptoms actually develop.
What to do right now if you’ve taken too much
- Call Poison Control at 1-800-222-1222 (US) for immediate, situation-specific guidance, or contact a medical toxicologist.
- Call your prescriber to let them know what happened, especially if you take other medications like insulin or a sulfonylurea.
- Go to the emergency room if you have severe or persistent vomiting, can’t keep fluids down, show signs of significant dehydration, have symptoms of low blood sugar that don’t resolve, or feel like something is seriously wrong.
- Don’t take your next scheduled dose early to “balance it out” — resume your normal one-tablet-daily schedule once you’ve been advised it’s safe to do so.
What this article won’t do
This article won’t tell you whether a specific amount you took is dangerous, and it won’t estimate how severe your symptoms might get — those depend on the exact amount taken, your health history, and other medications, none of which a general article can weigh for you. It also won’t substitute for actually calling Poison Control or your prescriber, which is the label’s own guidance, not just a suggestion.
Bottom line
There’s no orforglipron-specific overdose syndrome described in the FDA label, and no specific antidote. If you’ve taken more than intended, contact Poison Control (1-800-222-1222) or your prescriber right away, watch for worsening GI symptoms or, if you’re on insulin or a sulfonylurea, low blood sugar, and seek emergency care for anything severe. Because orforglipron’s half-life runs 1 to 2 days, don’t assume symptoms will resolve within hours — a period of observation is part of the label’s own guidance.
For the routine, correct way to take orforglipron day to day, see How to Take Orforglipron, and for what a single missed dose calls for instead, see Missed a Dose of Orforglipron?.
Frequently asked questions
What happens if you take too much orforglipron?
The FDA-approved FOUNDAYO label doesn't describe a specific overdose syndrome unique to orforglipron. Its overdosage guidance is general: in the event of an overdose, contact Poison Control or a medical toxicologist, and initiate supportive treatment based on the person's actual clinical signs and symptoms. Because orforglipron's effects build gradually and its half-life runs about 29 to 49 hours, a period of observation may be needed rather than a same-day resolution.
What symptoms should I watch for after taking too much orforglipron?
GLP-1 receptor agonists as a class are most associated with gastrointestinal effects, so worsened or severe nausea, vomiting, or diarrhea are the symptoms most likely to show up after taking more than intended. If you also take insulin or a sulfonylurea, low blood sugar (hypoglycemia) is an additional risk to watch for — symptoms include shakiness, sweating, confusion, or lightheadedness.
Is accidentally doubling a dose the same as an overdose?
Not necessarily the same severity, but the label treats doubling up as something to actively avoid — its missed-dose instructions explicitly say not to take an extra tablet to make up for a missed one. If you've taken two tablets in one day, that's a situation worth calling your prescriber or Poison Control about rather than waiting to see what happens, especially if symptoms develop.
Is there an antidote for an orforglipron overdose?
The FDA label doesn't describe a specific antidote or reversal agent. Management is supportive — treating whatever symptoms actually appear — rather than a single fix, which is consistent with how GLP-1 receptor agonist overdose is generally handled per drug labeling for this class.
When should I go to the emergency room instead of just calling my prescriber?
Seek emergency care for severe or persistent vomiting that prevents you from keeping fluids down, signs of significant dehydration, symptoms of low blood sugar that don't resolve, fainting, or any symptom that feels severe or rapidly worsening. For a single accidental extra dose with no or mild symptoms, calling Poison Control (1-800-222-1222) or your prescriber first is a reasonable starting point — they can help you decide whether ER care is needed.
How long could overdose symptoms last?
There's no fixed timeline in the label, but orforglipron's roughly 29-to-49-hour half-life means it doesn't clear quickly, so symptoms could plausibly persist or recur over a day or more rather than resolving within hours. That's part of why the label notes a period of observation may be necessary. Your prescriber or a toxicologist is best positioned to tell you what to expect for your specific situation.
Sources
- FOUNDAYO (orforglipron) tablets — FDA-approved label (DailyMed)
- Semaglutide Injection (Ozempic, Wegovy) — MedlinePlus Drug Information (NIH/NLM)
- Semaglutide Oral Tablet (Rybelsus) — MedlinePlus Drug Information (NIH/NLM)
- Tirzepatide Injection (Mounjaro, Zepbound) — MedlinePlus Drug Information (NIH/NLM)
Tracking an oral GLP-1?
GLPill logs your daily pill, times the 30-minute wait, and charts your progress — privately.
Get the app →